146 related articles for article (PubMed ID: 33846999)
1. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
[No Abstract] [Full Text] [Related]
2. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
3. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
[No Abstract] [Full Text] [Related]
5. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
[No Abstract] [Full Text] [Related]
6. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
7. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
[No Abstract] [Full Text] [Related]
8. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
9. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
10. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
Rapisuwon S; Izar B; Batenchuk C; Avila A; Mei S; Sorger P; Parks JM; Cooper SJ; Wagner D; Zeck JC; Charabaty AJ; Atkins MB
J Immunother Cancer; 2019 Mar; 7(1):61. PubMed ID: 30832716
[TBL] [Abstract][Full Text] [Related]
11. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
12. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
Noble CW; Gangaputra SS; Thompson IA; Yuan A; Apolo AB; Lee JM; Papaliodis GN; Kodati S; Bishop R; Magone MT; Sobrin L; Sen HN
Ocul Immunol Inflamm; 2020 Aug; 28(6):854-859. PubMed ID: 31013173
[TBL] [Abstract][Full Text] [Related]
13. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
[No Abstract] [Full Text] [Related]
14. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
15. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
16. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
18. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
19. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
20. BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION MISTAKEN FOR NIVOLUMAB-INDUCED VOGT-KOYANAGI-HARADA DISEASE-LIKE SYNDROME.
Dallinga MG; Bolhuis K; Bins A; de Hoog J
Retin Cases Brief Rep; 2024 May; 18(3):332-336. PubMed ID: 36728009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
